"We have suffered a significant financial loss as a consequence of Vifor's conduct," says Pharmacosmos

The Swiss firm has demonstrated anticompetitive behavior for 12 years on markets where it competes with Pharmacosmos, claims the Danish firm after having officially complained to the EU Commission.

Pharmacosmos's chief operating officer, Tobias S. Christensen (right), and chief executive officer, Lars Christensen (left) | Photo: Pharmacosmos / PR

For years on end, Vifor Pharma has been shutting out Pharmacosmos from the intravenous (IV) iron deficiency drug market, says the Danish family-owned business, claiming it has consequently lost out on considerable income.

Pharmacosmos finally saw no other option than to complain directly to the EU Commission over the alleged anticompetitive behavior, which reportedly included a year-long campaign to disparage the safety of the Danish drugmarker’s Monofer, in an attempt to stifle competition for its own IV iron deficiency treatment, the blockbuster drug Ferinject.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs